reata may25

Reata Pharmaceuticals Inc. (RETA) has reported positive interim data from its phase II study, dubbed PHOENIX.

The PHOENIX study is evaluating the Company's lead product candidate Bardoxolone methyl in three cohorts of patients - autosomal dominant polycystic kidney disease (ADPKD), IgA nephropathy, and type 1 diabetic Chronic Kidney Disease (T1D CKD).

The interim data reported on Friday, shows that Bardoxolone methyl improved kidney function in patients with autosomal dominant polycystic kidney disease and IgA Nephropathy.

In the ADPKD cohort, which involved 31 patients, Bardoxolone methyl significantly improved kidney function - showing a mean improvement of 6.6 mL/min/1.73 m2 at Week 4, increasing to 12.0 mL/min/1.73 m2 at Week 12.

In the IgA nephropathy cohort, which enrolled 26 patients, Bardoxolone-treated patients showed a mean improvement in  estimated glomerular filtration rate (eGFR)  of 8.4 mL/min/1.73 m2 at Week 8 from a mean baseline eGFR of 46.2 mL/min/1.73 m2. 

No drug-related serious adverse events have been reported, and reported adverse events have generally been mild to moderate in intensity, according to the Company. 

The Company expects to report full data for the primary endpoint of change in eGFR at Week 12 for the ADPKD, IgA nephropathy, and type 1 diabetic chronic kidney disease (CKD) cohorts in the third quarter of 2018.

The primary efficacy endpoint is change from baseline in eGFR after 12 weeks of treatment. Endpoints will be assessed for each cohort separately, according to the Company.

RETA closed Thursday's trading at $33.99, up 2.29%.

Related Reading

An Ear To The Pharma: 11 Stocks To Watch (DOVA, SESN, URGN…)

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT